Signs of life the growth of biotechnology centers in the u s
Download
1 / 28

Signs of Life The Growth of Biotechnology Centers in the U.S. - PowerPoint PPT Presentation


  • 232 Views
  • Uploaded on

Signs of Life The Growth of Biotechnology Centers in the U.S. Joseph Cortright Heike Mayer. The Brookings Institution Center on Urban and Metropolitan Policy  June 2002. Roadmap. Introduction to Biotech Industry Key Findings Detailed Results Lessons. Trends in Economic Development.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' Signs of Life The Growth of Biotechnology Centers in the U.S.' - Philip


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Signs of life the growth of biotechnology centers in the u s l.jpg

Signs of LifeThe Growth of Biotechnology Centers in the U.S.

Joseph Cortright

Heike Mayer

The Brookings Institution Center on Urban and Metropolitan Policy  June 2002


Roadmap l.jpg
Roadmap

  • Introduction to Biotech Industry

  • Key Findings

  • Detailed Results

  • Lessons


Trends in economic development l.jpg
Trends in Economic Development

  • The Next Silicon Valley

  • Battle for the Dot.Coms

  • Biotech: NBT (The Next Big Thing)

    • 83% of local development agenciesplace bio among their top two priorities

    • 41 States have biotech programs


Definitions methods l.jpg
Definitions & Methods

  • Biotechnology

    • Firms using genetic and cellular techniques

    • Biomedicine: diagnostic/therapeutic

    • Industry-developed definitions & data

  • Top 51 Metropolitan Areas

    • Census-defined CMSA/PMSA list


Industry segmentation l.jpg
Industry Segmentation

Pharmaceuticals

  • Very large, global firms

    • Top ten average $15 billion sales

  • Assets are products, distribution, manufacturing expertise

  • Very Profitable

Biotechnology

  • Small, mostly single establishment firms

    • Top ten average $700 million sales

  • Principal assets are people, research and future potential

  • Lose Money


Biotech basics l.jpg
Biotech Basics

  • 25,000 NIH-funded research projects

  • 5,000 biomedical patents

  • 400-500 drugs in development

  • 100 drugs on or near market

  • 10 products account for nearly all sales


Nine metros dominate l.jpg
Nine Metros Dominate

Seattle

Boston

New York

Philadelphia

San Francisco

Pharmaceutical Centers

Biotech Leaders

Biotech Challengers

Why these nine?

Special Cases

Washington-

Los Angeles

Research Triangle Park

San Diego


Two pillars of biotech development l.jpg

NIH Grants

Patents

Venture Capital

R&D Partnerships

Startup Firms

Established Firms

Two Pillars of Biotech Development

Research

Commercialization


Leaders vs the pack l.jpg
Leaders vs. the Pack

Average Levels of Activity

Top 9 Bottom

Metric Centers 42

NIH$ (millions) 812 104

Patents 2,641 263

Venture Capital 957 27

R&D Alliances 1,089 11

New Firms 35 2.3

Large Firms 24 1.5

_________

Biotech VC Firms 47 4


Research dispersing l.jpg
Research Dispersing

Top 9 Centers Share

1980s 1990s

NIH$ 63% 59%

Patents 71% 68%


Commercialization concentrating l.jpg
Commercialization Concentrating

Top 9 Centers Share

1980s 1990s

Venture Capital* 81% 86%

R&D Alliances* 89% 96%

New Firms 61% 77%

*Base data from early to mid-1990s


Nih funding l.jpg
NIH Funding

Research Grants, 2000 (Millions)

3rd


Biotech related patents l.jpg
Biotech Related Patents

Patents Awarded, 1990-1999

5th


Venture capital l.jpg
Venture Capital

Investment, 1995-2001 (Millions)

9th


R d alliances l.jpg
R&D Alliances

Value of R&D Alliances, 1996-2001 (Millions)

6th


Biotech startups l.jpg
Biotech Startups

New Biotech Firms Started Since 1990

6th


Established biotech companies l.jpg
Established Biotech Companies

Firms with 100 or more employees

4th


Washington baltimore cluster l.jpg
Washington/Baltimore Cluster

  • Research Assets

    • Johns Hopkins, National Institutes of Health

  • Cadre of Biotech Firms

    • Human Genome Sciences, Celera, Med-Immune, Alpharma, Genvec, Neurologic, Macrogenics

    • Dozens of others in biotech & related fields

  • BIO: National Industry Association


Washington baltimore report card l.jpg
Washington/Baltimore Report Card

  • Clearly among the top 9

  • Very strong in research

    • High levels of NIH funding

    • High volume of patents

  • Not as strong in commercialization

    • $85 million in venture capital

    • $17 million in R&D alliances with big Pharma

    • Heavily concentrated in Rockville-Gaithersburg


Four lessons l.jpg
Four Lessons

  • Biotech tends to cluster

  • Leaders have an edge

  • Entrepreneurship & venture capital are key

  • Outlook for biotech-led economic development


Biotech tends to cluster l.jpg
Biotech Tends to Cluster

  • Talent is drawn to where firms are; firms form where talent is

  • Powerful business advantages from agglomerations

  • A case of QWERTYnomics

    • Lock-in to particular arrangements


Leaders have an edge l.jpg
Leaders have an Edge

  • Falling (further) behind the Leaders

  • Biotech is concentrated and growing moreso

  • Leaders are:

    • 5 to 10x bigger than followers in research and

    • 30 to 100x bigger than followers in commercialization


Entrepreneurship is key l.jpg
Entrepreneurship is Key

  • Research base is necessary but not sufficient

  • Commercialization Assets

    • Entrepreneurial researchers

    • Industry-relevant talent

      • Technical

      • Managerial

    • Venture capital--surprisingly localized


Outlook for the bottom 42 l.jpg
Outlook for the “Bottom 42”

  • Biotech strategies are

    • Expensive

    • Risky

    • Time-consuming


Modest payoffs so far l.jpg
Modest payoffs, so far

  • No biotech firm is among 25 largest private employers in a metro

  • Biotech averages about 3.5% of manufacturing employment in 9 leading centers

  • Most biotech firms stay small; successful firms sell or license to big Pharma


A flawed analogy l.jpg
A flawed analogy?

  • Is biotech the next big thing?

  • Real breakthroughs and benefits, but:

    • No “Moore’s Law” for biotech

    • Not progressively less expensive than preceding generations of projects

  • More like nuclear power?


Conclusions l.jpg
Conclusions

  • Place still matters, even in a quintessential knowledge industry

  • Not just research, but the ability to turn ideas into businesses

  • The power of clustering provides decisive business advantages



ad